This is a Phase 1b open-label study of CPI-444, an oral, small molecule inhibitor targeting adenosine-2A receptors (A2AR), on safety/tolerability and efficacy as a single agent and in combination with daratumumab, a monoclonal antibody targeting CD38, in relapsed or refractory multiple myeloma.
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
The following is a listing of trial locations that are open and accepting patients.
There are no resources, links or videos to display for this clinical trial.